Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Josep M. Llovet, Arndt Vogel, David C. Madoff, et al.
CardioVascular and Interventional Radiology (2022) Vol. 45, Iss. 4, pp. 405-412
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1316
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 155
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
Deniz Tümen, Philipp Heumann, Karsten Gülow, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3202-3202
Open Access | Times Cited: 81
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102622-102622
Open Access | Times Cited: 44
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 42
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Nan Zhang, Yang Xu, Mingjian Piao, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 30
Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation
Alexandre Pérez-López, Cristina Martín‐Sabroso, Laura Gómez-Lázaro, et al.
Acta Biomaterialia (2022) Vol. 149, pp. 1-15
Open Access | Times Cited: 54
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, et al.
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 193-202
Open Access | Times Cited: 22
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 10
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
Huaxiang Wang, Junjun Li, Xiuling Zhu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Comparative Efficacy of Lenvatinib Plus Immunotherapy and Regorafenib Plus Immunotherapy After Lenvatinib Failure for Advanced Hepatocellular Carcinoma: A Retrospective Study
Zeyu Yu, Bin Leng, Ran You, et al.
Drugs - Real World Outcomes (2025)
Open Access | Times Cited: 1
Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
Jian Qin, Yu‐Sheng Huang, Hanjing Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 30
Transarterial Chemoembolization Treatment Paradigms for Hepatocellular Carcinoma
E. Fité, Mina S. Makary
Cancers (2024) Vol. 16, Iss. 13, pp. 2430-2430
Open Access | Times Cited: 7
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma
Sheng Ye, Qing Wang, Haifeng Liu, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1155, pp. 668-679
Closed Access | Times Cited: 6
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 909-923
Open Access | Times Cited: 15
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Samantha M. Ruff, Ashish Manne, Jordan M. Cloyd, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5863-5875
Open Access | Times Cited: 13
TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis
Jiaxi Liu, Peng Wang, Liqi Shang, et al.
Hepatology International (2023) Vol. 18, Iss. 2, pp. 595-609
Closed Access | Times Cited: 13
Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2024) Vol. 13, Iss. 3, pp. 227-234
Open Access | Times Cited: 5
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance
Yumin Fu, Xinyu Guo, Linmao Sun, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 5
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches
Shabnam Eghbali, Thatcher Heumann
Cancers (2025) Vol. 17, Iss. 2, pp. 236-236
Open Access
Early release of circulating tumor cells after transarterial chemoembolization hinders therapeutic response in patients with hepatocellular carcinoma
María Lola Espejo-Cruz, Sandra González‐Rubio, J.J. Espejo, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma
Stuart K. Roberts, Ammar Majeed, Kiran Rasaratnam, et al.
Cancer Medicine (2025) Vol. 14, Iss. 5
Open Access
Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria
Ji‐hoon Kim, Jin Hyoung Kim, Eun Jae Ko, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 894-894
Open Access
Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment
Kristin E. Goodsell, Alice Tao, James O. Park
Frontiers in Surgery (2025) Vol. 12
Open Access
Page 1 - Next Page

Scroll to top